Heart failure causally linked to chronic kidney disease
Medical Xpress - Cardiology
DECEMBER 19, 2023
Heart failure is causally associated with chronic kidney disease (CKD), according to a study published online Dec. 11 in PLOS ONE.
Finerenone Treatment Slows Chronic Kidney Disease Progression After Heart Failure Hospitalization
HCPLive
MAY 20, 2024
A numerically slower decline in eGFR was reported in the finerenone cohort after hospitalization for heart failure when compared with placebo.
Heart Failure 
116
116 
Incident heart failure and the subsequent risk of progression to end stage kidney disease in individuals with type 2 diabetes
Cardiovascular Diabetology
JUNE 14, 2024
Diabetic kidney disease is an established risk factor for heart failure. However, the impact of incident heart failure on the subsequent risk of renal failure has not been systematically assessed in diabetic p.
Abstract 4142036: Association of smoking status with incident heart failure among patients with chronic kidney disease: Insights from CRIC
Circulation
NOVEMBER 11, 2024
Introduction:Smoking is a well-known risk factor for atherosclerotic cardiovascular disease and kidney failure among patients with chronic kidney disease (CKD). However, the association of former and current smoking status (vs.
Evaluation and Management of Kidney Dysfunction in Advanced Heart Failure: A Scientific Statement From the American Heart Association
Circulation
SEPTEMBER 10, 2024
Early identification of kidney dysfunction in patients with advanced heart failure is crucial for timely interventions. In addition to elevations in serum creatinine, kidney dysfunction encompasses inadequate maintenance of sodium and volume homeostasis, retention of uremic solutes, and disrupted endocrine functions.
Finerenone’s Early Heart Failure Impact
CardiacWire
OCTOBER 6, 2024
Finerenone is already approved to reduce cardiovascular and kidney disease risks in patients with type 2 diabetes-associated CKD, but not for HF. The post Finerenone’s Early Heart Failure Impact appeared first on Cardiac Wire. And with a new drug, knowing which patients to target is a good way to start.
Kidney Dysfunction May Predict Sudden Cardiac Death in Patients with Heart Failure
DAIC
JULY 30, 2024
This study by Fujita Health University researchers revealed that kidney function, considered in terms of estimated glomerular filtration rate (eGFR), can be used as a predictor for SCD in patients with congestive heart failure. During the follow-up period, 198 of these patients suffered from SCD.
Advance in the Treatment of Acute Heart Failure Identified
DAIC
APRIL 30, 2024
Getty Images milla1cf Tue, 04/30/2024 - 12:56 April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center ( VUMC ) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure , a leading cause of hospitalization and death. hospitals from emergency rooms.
Heart Failure 105
105 
Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: data from Swedish Heart Failure Registry
European Journal of Heart Failure
OCTOBER 18, 2023
Mineralocorticoid receptor antagonist (MRA) use in severe chronic kidney disease and heart failure with reduced ejection fraction (HFrEF). Methods and results We analysed patients with HFrEF (ejection fraction <40%), not on dialysis, from the Swedish Heart Failure Registry.
Screening and Prevention for CKD
HCPLive
NOVEMBER 11, 2024
Panelists discuss the criteria for identifying at-risk patients for chronic kidney disease (CKD) testing in type 2 diabetes and review the screening and detection tests, emphasizing the critical importance of early detection through blood and urine tests for both CKD management and heart failure prevention.
Absolute, Functional Iron Deficiency Affects Large Proportion of US Adults
HCPLive
SEPTEMBER 26, 2024
Rates of absolute and functional iron deficiency were high among adults in the US, even in those without anemia, heart failure, or chronic kidney disease.
Kidney Disease 105
105 
Hyperuricaemia elevates risk of short-term readmission and mortality in patients with heart failure
Open Heart
OCTOBER 31, 2024
Background Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Results Baseline characteristics revealed significant differences between NUA and HUA groups, with the latter exhibiting a higher prevalence of males, chronic kidney disease (CKD) and elevated levels of various biomarkers.
Abstract 4143844: Multidisciplinary management of a pregnant patient with advanced systolic heart failure
Circulation
NOVEMBER 11, 2024
A 35-year-old gravida 1, para 0 with biventricular heart failure (LVEF 25%), nonischemic cardiomyopathy, history stroke, history of left ventricular thrombus, class III obesity, and chronic kidney disease who had been followed by Cardio-Obstetrics throughout her pregnancy presented at 34 weeks gestation for planned induction of labor.
Abstract 4146863: Efficacy of Hydralazine-Isosorbide-Dinitrate and Sodium-glucose Cotransporter-2 Inhibitors in Reducing Short-Term Readmission in African Americans with Advanced Heart Failure
Circulation
NOVEMBER 11, 2024
Introduction:The treatment of heart failure (HF) with hydralazine-isosorbide dinitrate (H-ISDN) in African Americans (AA) with New York Heart Association (NYHA) III-IV who remain symptomatic despite optimal medical therapy is a class Ia indication.
Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database
Cardiovascular Diabetology
JANUARY 8, 2024
Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.
Consensus document on palliative care in cardiorenal patients
Frontiers in Cardiovascular Medicine
DECEMBER 18, 2023
Chronic kidney disease coexists in up to 40%–50% of patients with chronic heart failure cases. There are guidelines for patients with heart failure and chronic kidney disease separately, but they do not specifically address patients with concomitant heart failure and kidney disease.
Document 93
93 
Chronic Kidney Disease Predisposes to Acute Congestive Heart Failure, Cardiogenic Shock, and Mortality in Patients Undergoing Percutaneous Coronary Intervention
The American Journal of Cardiology
OCTOBER 5, 2024
Publication date: Available online 5 October 2024 Source: The American Journal of Cardiology Author(s): Meghana Iyer, Khaled Ziada, Leslie Cho, Jacqueline Tamis-Holland, Umesh Khot, Amar Krishnaswamy, Rishi Puri, Samir Kapadia, Grant W Reed
Characterisation of the octogenarians presenting to the diagnostic heart failure clinic: SHEAF registry
Open Heart
APRIL 24, 2024
Introduction Heart failure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. Frailty, chronic kidney disease and ischaemic heart disease increased significantly versus the first period (p<0.001). Treatment is complicated by side effects and comorbidities.
Abstract 4147019: Role of Fractional Excretion of Uric Acid as a Predictor of Cardio-renal Syndrome in Acute Decompensated Heart Failure Patients: An Observational Study
Circulation
NOVEMBER 11, 2024
However, multi-parametric techniques and biomarkers which are available for investigating cardiovascular diseases and kidney diseases may offer opportunities for the evaluation of CRS. Circulation, Volume 150, Issue Suppl_1 , Page A4147019-A4147019, November 12, 2024.
5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC)
Cardiometabolic Health Congress
NOVEMBER 14, 2024
Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. Disparities in care are also concerning, with diagnosed cardiometabolic diseases varying up to twofold among different racial and ethnic groups. In the U.S.,
CME 96
96 
Multi-Ethnic Study of Atherosclerosis Early Heart Failure Study: Rationale, Design, and Baseline Characteristics
Circulation: Heart Failure
MARCH 8, 2024
Circulation: Heart Failure, Ahead of Print. Background:Current prevalence estimates of heart failure (HF) are primarily based on self-report or HF hospitalizations. Overt cardiovascular disease, which ranged from 2.1% (HF) to 13.6% (atrial fibrillation), was less common. were female, 25.6% were Black, 12.8%
2023 ESH Hypertension Guideline Update: Bringing Us Closer Together Across the Pond
American College of Cardiology
FEBRUARY 5, 2024
Hypertension represents a major modifiable risk factor for coronary artery disease (CAD), heart failure (HF), stroke, chronic kidney disease (CKD), and dementia.
Hypertension 75
75 
Abstract 4113864: Hyperkalemia In Patients With Heart Failure Correlates to Worse Inpatient Outcomes
Circulation
NOVEMBER 11, 2024
Patients with hyperkalemia had a higher frequency of diabetes mellitus, hypertension, chronic liver disease, acute kidney injury, chronic kidney disease, end-stage renal disease, and acute encephalopathy (p<0.001).
Inpatient 40
40 The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry
European Journal of Heart Failure
DECEMBER 22, 2023
ABSTRACT Aims The aim of this analysis was to provide data on the overall comorbidity burden, both cardiovascular (CV) and non-CV, in a large real-world heart failure (HF) population across the ejection fraction (EF). 1.65), chronic kidney disease (HR 1.37, 95%CI 1.34-1.41),
Estimated Glomerular Filtration Rate and Implantable Cardioverter?Defibrillator in Nonischemic Systolic Heart Failure: Extended Follow?Up of DANISH
Journal of the American Heart Association
JANUARY 31, 2024
Journal of the American Heart Association, Ahead of Print. BackgroundPatients with heart failure and chronic kidney disease (CKD) may have an increased risk of death from causes competing with arrhythmic death, which could have implications for the efficacy of implantable cardioverter‐defibrillators (ICDs).
SGLT-2 Inhibitors Show Mixed Results After Heart Attack
DAIC
APRIL 6, 2024
However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. All secondary endpoints related specifically to heart failure outcomes were significantly reduced among patients who received empagliflozin.
Heart Attack 98
98 
Cardiovascular medication in patients with raised NT-proBNP, but no heart failure in the SHEAF registry
Open Heart
JUNE 1, 2022
Objectives We aim to assess the association of cardiovascular medications with outcomes of patients referred to the diagnostic heart failure (HF) clinic with symptoms or signs of possible HF, raised N-terminal pro-brain-type natriuretic peptide (NT-proBNP) but no evidence of HF on transthoracic echocardiography (TTE).
Effects of empaglifozin on collagen biomarkers in patients with Heart Failure. Findings from the EMPEROR trials
European Journal of Heart Failure
DECEMBER 1, 2023
Abstract Background Extracellular matrix remodeling is one of the key pathways involved in heart failure (HF) progression. SGLT2 inhibitors may have a role in attenuating myocardial fibrosis. The impact of SGLT2 inhibitors on blood markers of collagen turnover in humans is not fully elucidated.
Understanding the failings of yesterday to improve the outcomes of tomorrow: a CardioRenal story
The British Journal of Cardiology
JULY 17, 2024
2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”
Predicting future atrial fibrillation: risk factors, proteomics and beyond
Heart BMJ
OCTOBER 10, 2024
The association between AF and various conditions—including hypertension, heart failure, sleep apnoea and chronic kidney disease—is well-described, highlighting that AF is often a multisystem disorder. 2 Before the.
Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR?Preserved analysis
European Journal of Heart Failure
MARCH 4, 2024
Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Empagliflozin reduced the risk of lower respiratory tract infections. CI, confidence interval; HR, hazard ratio. Aims Lower respiratory tract infections (LRTI) are common worldwide.
Home Hospital Outcomes for Acute Decompensated Heart Failure and Factors Associated With Escalation of Care
Circulation: Cardiovascular Quality & Outcomes
DECEMBER 6, 2023
Background:Overall outcomes and the escalation rate for home hospital admissions for heart failure (HF) are not known. had chronic kidney disease, and 60.6% Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. were women, and 64.8% were White. Of the cohort, 29.2% had reduced ejection fraction, 50.9%
Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease
Cardiovascular Diabetology
AUGUST 6, 2024
Data on major cardiovascular events (MACE; mortality, myocardial infarction, stroke, heart failure) through December 2021 were obtained from national registries. Furthermore, compared with other GLD, the use of cardioprotective GLD was more common in patients with a less frequent history of heart failure (5.0%
EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack
DAIC
APRIL 6, 2024
While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,
Heart Attack 81
81 Development and Validation of AHA’s PREVENT Equations
American College of Cardiology
FEBRUARY 12, 2024
What is the value of the new American Heart Association’s (AHA’s) PREVENT equation(s) for primary prevention that use routinely available clinical variables including obesity, diabetes, kidney disease, and social risk for predicting 10- and 30-year absolute risk of cardiovascular disease (CVD) including each atherosclerotic CVD (ASCVD) and heart (..)
Kidney Week 2023: Top Ten Takeaways
Cardiometabolic Health Congress
NOVEMBER 16, 2023
Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.
Comparison of Effectiveness Among Different Sodium?Glucose Cotransoporter?2 Inhibitors According to Underlying Conditions: A Network Meta?Analysis of Randomized Controlled Trials
Journal of the American Heart Association
JANUARY 31, 2024
The primary efficacy end point was the composite of cardiovascular death and hospitalizations for heart failure. The secondary efficacy end points were all‐cause death, cardiovascular death, hospitalizations for heart failure, kidney disease progression, and acute kidney injury.
America’s Growing CVD Problem
CardiacWire
OCTOBER 27, 2024
It’s well known that heart disease is the U.S.’s s top cause of death, and our rising CVD rates have been widely covered, but a look back on some of the biggest stories of 2024 suggests that cardiovascular disease is about to become a much bigger problem. trillion, representing 4.6%
AFIB 59
59 
Multispecialty multidisciplinary input into comorbidities along with treatment optimisation in heart failure reduces hospitalisation and clinic attendance
Open Heart
JULY 20, 2022
Aims Heart failure (HF) is associated with comorbidities which independently influence treatment response and outcomes. post-MDT; p<0.001), initiation of renin–angiotensin aldosterone system inhibitors in HF with reduced ejection fraction (HFrEF) with advanced chronic kidney disease (9% pre vs 71% post-MDT; p<0.001).
Albuminuria: An Underappreciated Risk Factor for Cardiovascular Disease
Journal of the American Heart Association
JANUARY 12, 2024
ABSTRACT: Albuminuria, an established biomarker of the progression of chronic kidney disease, is also recognized as a biomarker for the risk of cardiovascular disease. Elevated urinary albumin excretion indicates kidney damage and systemic vascular disease, including myocardial capillary disease and arterial stiffness.
Cardiorenal effects of therapies for type 2 diabetes and obesity
The British Journal of Cardiology
OCTOBER 8, 2024
Several recent clinical trials have provided evidence that these agents can decrease the risk of, and slow progression of, cardiovascular and renal diseases independently of their glucose-lowering and weight-lowering effects.
Obesity 52
52 Abstract 4121215: Efficacy and Safety of Empagliflozin in Patients with Acute Myocardial Infarction: A meta-analysis of randomized controlled trials
Circulation
NOVEMBER 11, 2024
Background:Empagliflozin is a sodium glucose co-transporter 2 inhibitor that improves cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidney disease and heart failure. vs 5.4%), and hospitalization for heart failure (RR 0.66; 95% CI [0.58, 0.76]; P < 0.00001; 3.2%
Abstract 4145840: Hypertensive Cardiorenal Disease with Cardiorenal Failure vs. Hypertensive Renal Disease with Renal Failure: Racial Mortality Trends from 1999 to 2020 in the United States
Circulation
NOVEMBER 11, 2024
The diagnosis of hypertension is associated with a significant increase in the risk of kidney or cardiovascular events, with no prior history of these events. Total deaths from hypertensive heart disease and renal disease associated with heart failure were 5,274, showing an increasing trend from 1999 to 2020.
Hypertension 40
40 Adverse Effects of Aldosterone: Beyond Blood Pressure
Journal of the American Heart Association
MARCH 18, 2024
However, activation of the MR across a wide distribution of tissue types has been implicated in multiple adverse consequences for cardiovascular, cerebrovascular, renal, and metabolic disease, independent of blood pressure alone.
Let's personalize your content